FOXP3 and autoimmune disease: Several authors including us (Pavlovic et al., 2018; Lu et al., 2019; Desbois et al., 2020; Lu et al., 2020) have shown that the administration of IL-33 had a significant effect on the increased regulatory FoxP3+ cells, which suppress autoimmune diseases including the MLD–STZ diabetes (Pavlovic et al., 2018).